中生北控生物科技股份有限公司是中國科學院和北京市政府的國有資產控股的高技術企業,以診斷產品的開發、生產和銷售為主業,是目前國內最大的生化診斷試劑公司。中生北控生物科技股份有限公司的前身是北京中生生物工程高技術公司,成立于1988年,是中國科學院生物物理研究所的所辦國有企業。2001年,中國科學院生物物理研究所以北京中生生物工程高技術公司整體投入發起改制,聯合北京市政府在香港的窗口企業北京控股有限公司、上海市政府旗下的聯創投資公司等股東投資創立并更名為中生北控生物科技股份有限公司。2006年2月27日,中生北控生物科技股份有限公司在香港聯交所創業板成功上市(股票代碼8247)。以此為標志,中生北控已經進入國際化、集團化、產品經營與資本經營復合化的嶄新發展階段。
公司成立以來,首創了中國“酶法診斷單、雙試劑”產品系列,成功開發了肝功類、血脂類、腎功類、心肌類、特種蛋白類、微量元素類、糖代謝類等系列試劑盒70多個品種、200多個規格單、雙生化試劑,診斷試劑系列產品歷年均被評為北京市新技術產業開發試驗區的“拳頭產品”,并被列入新技術企業50強《龍虎榜》,成為我國臨床診斷試劑市場公認的“國產名牌產品”。酶法診斷試劑盒系列產品技術榮獲1989年中國科學院科技進步3等獎、試驗區1989年優秀成果獎。1993年中生公司第一個在中國推出上機雙試劑,成為國家臨檢中心認可的上日立全自動生化儀的公司之一。中生公司的雙試劑已在日立(HITACHI)、奧林帕斯(OLYMPUS)、貝克曼(BECKMAN)等全自動生化分析儀上得到普遍使用,極大地方便了用戶,很受用戶歡迎。經過近二十年的發展,中生公司已經擁有了500多家代理商和銷售商,擁有了該行業75%以上的用戶,形成了覆蓋全國的銷售網絡。
公司嚴格按照GMP標準建立新廠房,擁有國內一流的設備;采用國際先進的生產工藝和管理模式,實現微機聯網和自動化聯線等先進的生產工藝。2002年,公司完成了ISO9001質量體系認證。公司自創建以來一直保持了良好的持續發展勢頭,其經營規模逐年擴大,銷售額穩定增長,成為中國科學院和北京市名列前茅的生物醫藥企業。
公司自主研發的酶法臨床診斷試劑盒于1989年同時榮獲中科院“科技進步三等獎”和北京市新技術產業開發試驗區“優秀科技成果”獎。
臨床診斷試劑系列從1990年以來歷年均被評為北京市新技術產業開發試驗區“拳頭產品”。2002年,公司的體外臨床診斷試劑又經北京市質量技術監督局、北京市經濟委員會共同評選為“北京名牌產品”。
Biosino Biotechnology Company Ltd is a high-technology enterprise whose major national controlling stakeholders comprise the Chinese Academy of Sciences, Beijing Municipal Government and Shanghai Municipal Government. Through the development, production and retail of diagnostic products, Biosino has become the largest manufacturer of diagnostic biochemical assay kits in China. Formerly established in 1988 as Beijing Zhong Sheng Bio-engineering High Technology Company, it was a national enterprise under the auspices of the Chinese Academy of Sciences Institute of Biophysics. In 2001, the Chinese Academy of Sciences Institute of Biophysics backed the re-launch of the company. With investment from Chuangkou Enterprises in Hong Kong owned by Beijing Municipal Government and from Shanghai Municipal Government's Lianchuang Investment Company, together with a new name, Biosino Biotechnology Company Ltd. was established.
Since its inception, Biosino has taken the lead within China in creating a series of mono- and double- reagent diagnostic products, successfully developing a series of more than 90 assay sets directed at conditions such as hepatitis, coronary artery disease, diabetes and hyperlipidemia. Our series of over 200 standard mono- and double- reagent diagnostic tests has been consistently recognized over the years to be a leading product from the Beijing New Technology Pilot Industrial Development Zone. What is more, our enterprise has been listed as one of the top 50 "New Technology Tigers", achieving recognition for our products as a famous brand nationally.
In 1989, our series of diagnostic chemical assay kits won the Chinese Academy of Sciences' Science and Technology Award (3rd level) and the Development Zone's Outstanding Achievement Award. In 1993, Biosino became the first company in China to produce double-reagents for use in automated equipment, gaining national recognition for reagents approved for use with the Hitachi fully automated biochemical analyzer. Biosino's double-reagent products are now well established and widely used with Hitachi, Olympus, Beckman and other such analyzers, used in major centers and well-received by customers. With over a dozen years of development, Biosino's products are now promoted by over 500 agents and retailers, occupy 75% of the market and enjoy a retail network that covers the whole country.
The company has built a new factory, strictly in accordance with GMP standards, which boasts the best facilities in China. Using advanced international production technology and management models, we have achieved a microcomputer-controlled, automated biochemical technology production system. In 2002, the company passed the ISO9001 quality inspection. Ever since it was founded, the company has always maintained its healthy momentum towards continued development, annual growth and stable expansion in marketing, becoming one of the leading names in biomedical enterprise at the Chinese Academy of Sciences as well as in Beijing.
In 1989, the clinical diagnostic chemical sets developed by our company won the Chinese Academy of Sciences "Progress in Science and Technology Award" (Third Class) as well as the Beijing New Technology Pilot Industrial Development Zone "Outstanding Science and Technology Achievement Award".
Over the years since 1990, our clinical diagnostic series has consistently been found to be a leading product from Beijing's New Technology Pilot Industrial Development Zone.In 2002, the company's in vitro clinical diagnostic reagents were again reviewed by the Beijing Technology Quality Control Office and judged to be a renowned Beijing brand.